Scientific instrument company Bruker (NASDAQ: BRKR). will be reporting earnings this Wednesday before market open. Here’s what to expect.
Bruker beat analysts’ revenue expectations last quarter, reporting revenues of $977.2 million, flat year on year. It was a satisfactory quarter for the company, with full-year revenue guidance exceeding analysts’ expectations but a significant miss of analysts’ EPS estimates.
Is Bruker a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Bruker’s revenue to be flat year on year, slowing from the 11% increase it recorded in the same quarter last year.
Heading into earnings, analysts covering the company have grown increasingly bullish with revenue estimates seeing in majority upward revisions over the last 30 days. Bruker has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Bruker’s peers in the life sciences tools & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Avantor posted flat year-on-year revenue, beating analysts’ expectations by 2.7%, and Thermo Fisher reported revenues up 6.2%, topping estimates by 1.5%. Avantor traded up 3.1% following the results while Thermo Fisher was down 8.6%.
Read our full analysis of Avantor’s results here and Thermo Fisher’s results here.
There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 5.7% on average over the last month. Bruker’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $46.79 (compared to the current share price of $36.39).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
